| Literature DB >> 35052671 |
Sulagna Dutta1,2, Pallav Sengupta2,3, Shubhadeep Roychoudhury4, Srikumar Chakravarthi1,3, Chee Woon Wang1, Petr Slama5.
Abstract
The pathophysiology of male infertility involves various interlinked endogenous pathways. About 50% of the cases of infertility in men are idiopathic, and oxidative stress (OS) reportedly serves as a central mechanism in impairing male fertility parameters. The endogenous antioxidant system operates to conserve the seminal redox homeostasis required for normal male reproduction. OS strikes when a generation of seminal reactive oxygen species (ROS) overwhelms endogenous antioxidant capacity. Thus, antioxidant treatment finds remarkable relevance in the case of idiopathic male infertility or subfertility. However, due to lack of proper detection of OS in male infertility, use of antioxidant(s) in some cases may be arbitrary or lead to overuse and induction of 'reductive stress'. Moreover, inflammation is closely linked to OS and may establish a vicious loop that is capable of disruption to male reproductive tissues. The result is exaggeration of cellular damage and disruption of male reproductive tissues. Therefore, limitations of antioxidant therapy in treating male infertility are the failure in the selection of specific treatments targeting inflammation and OS simultaneously, two of the core mechanisms of male infertility. The present review aims to elucidate the antioxidant paradox in male infertility treatment, from the viewpoints of both induction of reductive stress as well as overlooking the inflammatory consequences.Entities:
Keywords: antioxidants; inflammation; male infertility; oxidative stress; reductive stress
Year: 2022 PMID: 35052671 PMCID: PMC8772926 DOI: 10.3390/antiox11010167
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Individual or combination antioxidant treatments with beneficial or no significant effects on semen quality.
| Antioxidant Regime | Study Population | Sperm Parameters | Study |
|---|---|---|---|
| Zinc sulphate (220 mg) for 4 months | oligospermic males ( | 21.4% (3/14) of patients achieved pregnancy | [ |
| 600 mg of vitamin E daily for 3 months | Infertility with high ROS | No change in SC, Smot and Smorph | [ |
| Zinc sulphate (500 mg) for 3 months | Asthenozoospermia ( | Improved pregnancy (22.5%) vs. placebo (4.3%) | [ |
| 1 g vitamin C and 800 mg vitamin E daily for 56 days | Asthenozoospermia | No change in SC, Smot and Smorph | [ |
| 1 g of vitamins C and E daily for 2 months | Idiopathic infertility (38 infertile men with previous IVF/ICSI) | No change in SC, Smot and Smorph | [ |
| L-carnitine 3 g daily; L-acetyl carnitine 3 g daily; L-carnitine (2 g daily) and L-acetyl carnitine combination (1 g daily) | Idiopathic asthenozoospermia (Placebo group = 15, L-carnitine group = 15; L-acetylcarnitine group = 15; L-carnitine and L-acetylcarnitine combined group = 15) | Increase in sperm motility and normal sperm morphology | [ |
| 1 g Carnitine and 500 mg L-acetyl carnitine daily for 24 weeks | Asthenozoospermia | No improvement in Smot | [ |
| 400 mg each vitamins C and E, 18 mg β-carotene, 500 μmol zinc, 1 μmol selenium daily for 90 days | 38 infertile men with At least two failed IVF or ICSI | Increased chromatin decondensation | [ |
| Menevit (lycopene, vitamins E, C, zinc, selenium, folate, garlic oil) daily for three months | 60 infertile men | No significant difference in DFI | [ |
| 300 mg selenium daily for 48 weeks | Normozoospermia | No improvement in Smot and Smorph | [ |
| Menevit (lycopene, vitamins E, C, zinc, selenium, folate, garlic oil) daily for three months | 50 infertile men with elevated OS | No change in SC, Smot and Smorph | [ |
| 500 mg L-carnitine, 60 mg vitamin C, 20 mg coenzyme Q10, 10 mg vitamin E, 200 µg vitamin B, 91 µg vitamin B12, 10 mg zinc, 50 µg selenium once daily for 3 months | Prospective observational study with 20 men with grade 1 varicocele and primary or secondary infertility | No change in SC, Smot and Smorph | [ |
| 30 mg vitamin C, 5 mg vitamin E, 0.5 µg vitamin B12, 750 mg L-carnitine, 10 mg coenzyme Q10, 100 µg folic acid, 5 mg zinc, 25 µg selenium twice daily for 6 months | 7 infertile men with sperm DFI >25%Treatment group (37 patients) Placebo group (40 patients) | No change in SC, DFI | [ |
| Coenzyme Q10 = 200 mg daily | Idiopathic infertility (Placebo group = 114, Treatment group = 114) | Increase in sperm concentration, motility, and normal sperm morphology | [ |
| L-carnitine = 1 g, L-acetylcarnitine = 0.5 g, fumarate = 0.725 g, fructose = 1 g, citric acid = 50 mg, zinc = 10 mg, coenzyme Q10 = 20 mg, selenium = 50 µg, Vit C = 90 mg, folic acid = 200 µg, Vit B12 = 1.5 µg daily for 3 months | Idiopathic oligoasthenozoospermia (Placebo group = 50, Treatment group = 50) | Increase in semen volume, progressive motility, and vitality in placebo group. Decrease in sperm DNA fragmentation index in treatment group. | [ |
| 5 mg folic acid, 30 mg zinc once daily for 6 months | 1773 men planning to undergo infertility treatment with spouse | No improvement in Smot and Smorph | [ |
SC = sperm concentration, Smot = sperm motility, and Smorph = sperm morphology, DFI = DNA fragmentation index.
Figure 1Mechanisms to explain ‘antioxidant paradox’ pertaining to male infertility, both by the induction of reductive stress and the failure to address the interconnected link of oxidative stress (OS) with inflammation. Various endogenous and exogenous factors may induce OS. OS and inflammatory pathways operate in loops, each triggering the other. Antioxidants act to mitigate excess reactive oxygen species (ROS) to minimize the adverse impacts of OS on male reproductive tissues. If overused, antioxidants may shift the redox scale towards the reductive end causing reductive stress rendering insufficient ROS needed for normal physiological functions of the sperms. Moreover, reductive stress also may revert to OS conditions. Finally, the antioxidants fail to curb the inflammatory responses that may again lead to OS and OS-induced male reproductive disruptions. ER = endoplasmic reticulum; MetS = metabolic syndrome; GSH = reduced glutathione; GSSG = oxidized glutathione; ROS = reactive oxygen species; RNS = reactive nitrogen species; GPx = glutathione peroxidase; Nrf2 = nuclear factor-erythroid factor-2-related factor-2; E2 = estradiol; NFkB = nuclear factor kappa B; MAPK = mitogen activating factor kinase; NO = nitric oxide; PG = prostaglandin.